<DOC>
	<DOCNO>NCT01377051</DOCNO>
	<brief_summary>The purpose study determine whether indacaterol maleate 300 microgram ( mcg ) effective acute treatment COPD particular reduce lung hyperinflation dynamic volume .</brief_summary>
	<brief_title>Effect Indacaterol Maleate Chronic Obstructive Pulmonary Disease ( COPD ) Lung Volume Related Dyspnea</brief_title>
	<detailed_description>Enrolled patient : COPD disease severity stable condition . 48 hour inhalatory drug wash . Evaluation : Plethysmographic test , blood gas analysis , blood pressure , cardiac frequency Borg scale evaluation basal condition 60 minute indacaterol maleate 300 mcg inhalation .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Signature consensus COPD diagnosis Age 50 85 year old history COPD least one year respiratory stable condition least one month Any basal FEV1 express % predict value FEV1/ Forced Vital Capacity ( FVC ) less 70 % Former active smoker least smoke history 20 pack year Pregnancy FEV1/FVC 70 % Known deficit alpha 1 antitrypsin Subjects submit Lung Volume Reduction Surgery ( LVRS ) Subjects know positivity Human Immunodeficiency Virus ( HIV ) Misuse alcool drug Absence compliance perform respiratory test</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Inspiratory capacity</keyword>
	<keyword>Residual volume</keyword>
	<keyword>Total lung resistance</keyword>
	<keyword>Arterial Oxygen</keyword>
</DOC>